OMT-28
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C18H32N2O5 |
| Molar mass | 356.463 g·mol−1 |
OMT-28 is a synthetic analog of omega-3 epoxyeicosatrienoic acids developed for atrial fibrillation.[1][2]
References
[edit]- ^ Berlin, Sarah; Goette, Andreas; Summo, Luciana; Lossie, Janine; Gebauer, Alexander; Al-Saady, Naab; Calo, Leonardo; Naccarelli, Gerald; Schunck, Wolf-Hagen; Fischer, Robert; Camm, A.John; Dobrev, Dobromir (August 2020). "Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study". IJC Heart & Vasculature. 29: 100573. doi:10.1016/j.ijcha.2020.100573. PMC 7356118. PMID 32685659.
- ^ Dan, Gheorghe-Andrei (6 August 2020). "Non-traditional antiarrhythmic drugs as upstream and downstream dam for atrial fibrillation burden". International Journal of Cardiology. Heart & Vasculature. 29: 100610. doi:10.1016/j.ijcha.2020.100610. ISSN 2352-9067. PMC 7452524. PMID 32885033.